- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01286818
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
October 3, 2014 updated by: Eli Lilly and Company
A Phase 1b Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with irinotecan, levofolinate, and 5-fluorouracil (FOLFIRI) in Japanese participants with advanced colorectal carcinoma (CRC).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Chiba, Japan, 277-8577
- ImClone Investigational Site
-
Osaka, Japan, 569-8686
- ImClone Investigational Site
-
Shizuoka, Japan, 411-8777
- ImClone Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is Japanese
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Has histologically or cytologically confirmed CRC
- Has metastatic disease that is not amenable to potentially curative resection
- Has received no more than 2 prior systemic chemotherapy regimens in any setting (only 1 prior regimen for metastatic disease is permitted)
- Has received first-line combination therapy of bevacizumab, oxaliplatin, and a fluoropyrimidine for metastatic disease and has experienced disease progression during first-line therapy, or disease progression within 6 months after the last dose of first-line therapy, or discontinued part or all of first-line therapy due to toxicity and experienced disease progression within 6 months after the last dose of first-line therapy. Participants must have received a minimum of 2 doses of bevacizumab as part of a first-line regimen containing chemotherapy in order to enroll.
- Has adequate hepatic, renal, hematologic, and coagulation function
- The participant's urinary protein is ≤1+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine must be collected and must demonstrate <1000 milligrams (mg) of protein in 24 hours to allow participation in the study
Exclusion Criteria:
- Has received bevacizumab within 28 days prior to study registration
- Has received chemotherapy within 21 days prior to study registration
- Has received any previous systemic therapy (other than a combination of bevacizumab, oxaliplatin, and a fluoropyrimidine) for first-line treatment of metastatic CRC
- The participant experienced any of the following during first-line therapy with a bevacizumab-containing regimen: an arterial thrombotic/thromboembolic event; Grade 4 hypertension; Grade 4 proteinuria; a Grade 3-4 bleeding event; or bowel perforation
- Has received wide-field (full-dose pelvic) radiotherapy within 28 days prior to study registration
- Has undergone major surgery within 28 days or subcutaneous venous access device placement within 7 days prior to study registration
- Has elective or planned surgery to be conducted during the trial
- Has a history of deep vein thrombosis or pulmonary embolism within the past 12 months
- Has experienced any arterial thrombotic event within the past 12 months
- Participant is receiving therapeutic anticoagulation with warfarin, low-molecular weight heparin, or similar agents
- Participant is receiving chronic therapy with nonsteroidal anti-inflammatory agents [Aspirin up to 325 milligrams per day (mg/day) permitted]
- Has a significant bleeding disorder or has had a significant (Grade 3 or higher) bleeding event within 3 months prior to registration date
- Has a history of gastrointestinal perforation and/or fistulae within 6 months prior to registration date
- Has symptomatic congestive heart failure, unstable angina pectoris, or symptomatic or poorly controlled cardiac arrhythmia
- Has uncontrolled arterial hypertension despite standard medical management
- Has a serious or nonhealing wound, peptic ulcer, or bone fracture within 28 days prior to study registration
- Has an acute/subacute bowel obstruction or history of clinically significant chronic diarrhea
- Has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months prior to registration date
- The participant has either peptic ulcer disease associated with a bleeding event or known active diverticulitis
- Has an active infection requiring antibiotic, antifungal, or antiviral therapy
- Has known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)-related illness
- Has known leptomeningeal or brain metastases or uncontrolled spinal cord compression
- Has a known history of Gilbert's Syndrome, or is known to have any of the following genotypes: uridine diphosphate glucuronosyltransferase 1 family, polypeptide A1 (UGT1A1)*6/*6; UGT1A1*28/*28 or UGT1A1*6/*28
- Has previous or concurrent malignancy, except for basal or squamous cell skin cancer and/or in situ carcinoma, or other solid tumors treated curatively and without evidence of recurrence for at least 3 years
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFIRI plus Ramucirumab (IMC-1121B)
|
Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
Other Names:
IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
IV infusion, 200 mg/m² every 2 weeks
400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants That Experienced Any Dose-Limiting Toxicities (DLT) During the DLT Assessment Period
Time Frame: Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)
|
DLTs were adverse events (AEs) possibly related to study drug that met the National Cancer Institute's Common Terminology Criteria for AEs (NCI CTCAE, version 4.03): Grade 4 neutropenia ≥7 days or ≥Grade 3 with bacteremia or sepsis; Absolute neutrophil count <1.0x10^9/Liters with fever ≥38.3°Celsius requiring intravenous antibiotic therapy; Grade 4 thrombocytopenia or ≥Grade 3 with bleeding requiring platelet transfusion; ≥Grade 3 altered coagulation tests and no anticoagulation; ≥Grade 4 or uncontrolled hypertension; ≥Grade 3 non-hematologic toxicity (except non-clinically significant Grade 3 events like electrolyte abnormality, hypersensitivity, and arthralgia/myalgia); urine protein >3 grams/24 hours; study drug-related toxicity causing Cycle 3, Day 1 treatment delay until Day 44 or later.
Grade 3 or Grade 4 infusion-related reaction (hypersensitivity) due to ramucirumab or FOLFIRI, not a DLT.
|
Day 1, Cycle 1 through Day 1, Cycle 3 (1 cycle=14 days)
|
Number of Participants With Ramucirumab Drug-Related Adverse Events or Serious Adverse Events
Time Frame: Baseline to end of study (up to 49.3 weeks) plus 37 day follow-up
|
Data are presented for the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade ≥3 TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab.
Events related to Irinotecan, Levofolinate, and 5-fluorouracil (5-FU) were reported separately.
A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.
|
Baseline to end of study (up to 49.3 weeks) plus 37 day follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Serum Anti-IMC-1121B Antibodies (Immunogenicity)
Time Frame: Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]
|
Day 1 of Cycle 5 (Week 9), Cycle 6 (Week 11), Cycle 7 (Week 13), and Cycle 9 (Week 17) [(1 cycle=14 days)]
|
|
Maximum Concentration (Cmax) of Ramucirumab
Time Frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
The Cmax of ramucirumab in serum on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered Cmax at steady state (Cmax,ss), is reported.
|
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Area Under the Curve (AUC) of Ramucirumab
Time Frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Reported for Day 1, Cycle 1 is AUC from time 0 extrapolated to infinity [AUC(0-inf)] and for Day 1, Cycle 5 is AUC over the dosing interval at steady state AUC(tau,ss).
|
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Half Life (t1/2) of Ramucirumab
Time Frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
t1/2 is the time required for the plasma/serum concentration to decrease 50%.
|
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Clearance (CL) of Ramucirumab
Time Frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
The total body CL of ramucirumab on Day 1, Cycle 1 and on Day 1, Cycle 5, which was also considered CL at steady state (CLss), is reported.
|
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Steady State Volume of Distribution (Vss) of Ramucirumab
Time Frame: Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Vss is the theoretical volume in which the total amount of study drug would need to be uniformly distributed during steady state to produce the same concentration as it is in plasma/serum.
|
Day 1, Cycle 1 and Day 1, Cycle 5 (1 cycle=14 days)
|
Best Overall Response [Anti-Tumor Activity of FOLFIRI Plus Ramucirumab (IMC-1121B)]
Time Frame: Every 8 weeks until PD (up to 49 weeks)
|
Best overall response evaluated using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) criteria.
Complete Response (CR): disappearance of all non-nodal target lesions, with the short axes of any target lymph nodes reduced to <10 millimeters (mm).
Partial Response (PR): at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph nodes), taking as reference the baseline sum diameter.
Progressive Disease (PD): an increase of at least 20% in the sum of the diameters of target lesions, taking as reference the smallest sum on study (included baseline sum if that was the smallest on study).
In addition, the sum must have demonstrated an absolute increase of at least 5 mm (the appearance of 1 or more new lesions was considered progression).
Stable Disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started.
|
Every 8 weeks until PD (up to 49 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
January 25, 2011
First Submitted That Met QC Criteria
January 28, 2011
First Posted (Estimate)
January 31, 2011
Study Record Updates
Last Update Posted (Estimate)
October 6, 2014
Last Update Submitted That Met QC Criteria
October 3, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Carcinoma
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Fluorouracil
- Leucovorin
- Irinotecan
- Levoleucovorin
- Ramucirumab
- Antibodies, Monoclonal
Other Study ID Numbers
- 14223
- CP12-1029 (Other Identifier: ImClone Systems)
- 14T-IE-JVBY (Other Identifier: Eli Lilly and Company)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Carcinoma
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingStage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Recurrent Colorectal Carcinoma | Metastatic Colorectal Carcinoma | Refractory Colorectal CarcinomaUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Roswell Park Cancer InstituteNot yet recruitingPembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)Recurrent Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal CarcinomaUnited States
-
Wuhan Union Hospital, ChinaNot yet recruitingRecurrent Colorectal Carcinoma | Advanced Colorectal CarcinomaChina
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Adenoma | Colorectal Carcinoma | Colorectal Adenoma and CarcinomaNetherlands
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Center for Advancing Translational Sciences (NCATS)Not yet recruitingRecurrent Colorectal Carcinoma | Locally Advanced Colorectal Carcinoma | Stage III Colorectal CancerUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)RecruitingMetastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingUnresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal CarcinomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingMetastatic Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma | Advanced Colorectal AdenocarcinomaUnited States
Clinical Trials on Ramucirumab (IMC-1121B)
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States, Canada, Belgium, Germany, Israel, Korea, Republic of, Spain, Australia, Austria, Brazil, France, Italy, Japan, Portugal, Taiwan, Romania, Bulgaria, Czech Republic, Finland, Hong Kong, Hungary, Netherlands, Norway, Phili... and more
-
Eli Lilly and CompanyCompletedHepatocellular CarcinomaUnited States
-
Eli Lilly and CompanyCompletedAdvanced Solid TumorsUnited States
-
Eli Lilly and CompanyParexelCompleted
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyNo longer availableMetastatic Gastric Cancer | Metastatic Adenocarcinoma of the Gastroesophageal JunctionGermany, Netherlands, Austria, Greece, Korea, Republic of
-
Eli Lilly and CompanyCompletedBreast CancerUnited States, Canada, Australia, Belgium, Brazil, Croatia, Czechia, Egypt, Germany, Ireland, Israel, Korea, Republic of, Lebanon, New Zealand, Peru, Poland, Russian Federation, Serbia, Slovakia, South Africa, Spain, Taiwan, United...
-
Eli Lilly and CompanyCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaUnited States, United Kingdom
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaUnited States, Poland, Romania, Hungary, Russian Federation, Australia, France, Argentina, United Kingdom, New Zealand, Turkey, Slovakia